Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Clin Cancer Res. 2011 Feb 23;17(11):3794–3802. doi: 10.1158/1078-0432.CCR-10-2056

Table 4.

Pharmacokinetic parameters of SJG-136 following daily × 5 intravenous administration of 6, 12, 24 or 48 µg/m2/day SJG-136 (Schedule A).

SJG-136 Dose Level (µg/m2/day)
6 (n=1) 12 (n=1) 24 (n=3) 48 (n=2)
Cmax
(ng/mL)		 C1D1 1.02 3.72 9.14 (1.57) 7.64
C1D5 0.98 4.83 6.77 (2.57) 7.54
AUCinf
(ng•min/mL)		 C1D1 46.7 163 470 (123) 333
C1D5 51.8 193 470 (304) 340
Half-life
(min)		 C1D1 125 82.6 124 (10) 81.7
C1D5 120 97.7 122 (11) 116
CL
(mL/min/m2)		 C1D1 129 73.5 53.2 (12.1) 144
C1D5 115 62.2 66.0 (35.9) 144
Vss
(mL/m2)		 C1D1 11500 4130 4350 (795) 10300
C1D5 10800 4050 7170 (2660) 12100